CA2778331A1 - Methods of using anti-cd3 antibodies to prevent weight gain - Google Patents

Methods of using anti-cd3 antibodies to prevent weight gain Download PDF

Info

Publication number
CA2778331A1
CA2778331A1 CA2778331A CA2778331A CA2778331A1 CA 2778331 A1 CA2778331 A1 CA 2778331A1 CA 2778331 A CA2778331 A CA 2778331A CA 2778331 A CA2778331 A CA 2778331A CA 2778331 A1 CA2778331 A1 CA 2778331A1
Authority
CA
Canada
Prior art keywords
antibody
antigen binding
binding fragment
day
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2778331A
Other languages
English (en)
French (fr)
Inventor
Aoife Brennan
Charlotte Mckee
Douglas Ringler
Lou Vaickus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CA2778331A1 publication Critical patent/CA2778331A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2778331A 2009-10-20 2010-10-20 Methods of using anti-cd3 antibodies to prevent weight gain Abandoned CA2778331A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25347409P 2009-10-20 2009-10-20
US61/253,474 2009-10-20
PCT/US2010/053433 WO2011050104A2 (en) 2009-10-20 2010-10-20 Methods of using anti-cd3 antibodies to prevent weight gain

Publications (1)

Publication Number Publication Date
CA2778331A1 true CA2778331A1 (en) 2011-04-28

Family

ID=43900946

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2778331A Abandoned CA2778331A1 (en) 2009-10-20 2010-10-20 Methods of using anti-cd3 antibodies to prevent weight gain

Country Status (5)

Country Link
US (1) US20130171142A1 (enExample)
EP (1) EP2490719A4 (enExample)
JP (1) JP2013508391A (enExample)
CA (1) CA2778331A1 (enExample)
WO (1) WO2011050104A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3504241B1 (en) * 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8064994B2 (en) * 2003-01-14 2011-11-22 The United States Of America As Represented By The Department Of Veterans Affairs Cervical vagal stimulation induced weight loss
WO2006096565A2 (en) * 2005-03-04 2006-09-14 Curedm Inc. Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与

Also Published As

Publication number Publication date
JP2013508391A (ja) 2013-03-07
EP2490719A2 (en) 2012-08-29
EP2490719A4 (en) 2013-11-06
WO2011050104A2 (en) 2011-04-28
US20130171142A1 (en) 2013-07-04
WO2011050104A3 (en) 2011-07-21

Similar Documents

Publication Publication Date Title
US20120269826A1 (en) Anti-cd3 antibody dosing in autoimmune disease
CA2718191C (en) Agent for treating disease
US20130095121A1 (en) Methods of treating patients with immune-related diseases
ES2610327T3 (es) Régimen de dosificación de anticuerpos anti-CD4 para el tratamiento de enfermedades autoinmunitarias
EP2265643B1 (en) Dosing regimen for treating psoriasis and rheumatoid arthritis
JP5997613B2 (ja) Ｄｌｌ４アンタゴニストによる自己免疫疾患の治療法
WO2007117600A2 (en) Combination therapy for treating autoimmune diseases
KR20180037984A (ko) 개선된 결합 특징, 기능적 특징 및 안전성 특징을 구비한 항-cd154 항체 및 인간 면역요법에서의 용도
KR20200119244A (ko) 이중 특이성 항체
TW201943731A (zh) 用於預防移植物排斥之抗cd40抗體
JP7572041B2 (ja) 重症喘息を処置するための組成物および方法
CN114599398A (zh) 用gm-csf拮抗剂治疗癌症
CA2778331A1 (en) Methods of using anti-cd3 antibodies to prevent weight gain
TWI875757B (zh) T1dm和胰島炎治療中使用之抗cd40抗體
WO2025128263A1 (en) Anti-pd-1 monoclonal antibody and methods of preparation thereof
US9512218B2 (en) Use of IL-20 antagonists for alleviating spinal cord injury
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
WO2014204898A1 (en) Use of il-20 antagonists for alleviating obesity
WO2021086997A1 (en) Treating tissue fibrosis and/or injury and-or organ failure with interleukin 24 or interleukin 20 antagonist
HK40042290A (en) Anti cd6 antibodies for treating severe asthma
HK1151533B (en) Agent for treating disease

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131023

FZDE Discontinued

Effective date: 20151020